Sexual wellness
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. · Int J Impot Res · 2004
PMID: 14999221 · DOI: 10.1038/sj.ijir.3901183
Summary
Phase 1 study characterizing subcutaneous PT-141 safety, PK and pharmacodynamics in healthy men and men with inadequate sildenafil response. Endpoints: tolerability, plasma exposure, RigiScan-measured response.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →PT-141Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
Guides covering this compound
More Sexual wellness citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet Gynecol · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot Res · 2004